{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:32:06Z","timestamp":1787776326140,"version":"build-2784847793"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>We report a 55-year-old men patient with a primitive central nervous system non-Hodgkin lymphoma B cell (LNH PNSLC), treated with chemotherapy rituximab, methotrexate, and ibrutinib (first treatment) who developed a refractory ventricular arrhythmic storm two hours after the ibrutinib intake. Indeed, ibrutinib could be associated with severe and occasionally fatal cardiac events. The swift emergence of a ventricular electrical storm with cardiac arrest demanded the prompt initiation of veno-arterial extracorporeal membrane oxygenation to effectively navigate this critically ill patient toward recovery. This intervention was deemed imperative, given the absence of any available antidote for the effects of ibrutinib. Veno-arterial extracorporeal membrane oxygenation proved successful in rescuing this patient, resulting in a complete neurological recovery. Consequently, he was able to resume his chemotherapy treatment.<\/jats:p>","DOI":"10.4103\/aca.aca_4_24","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T07:16:00Z","timestamp":1724915760000},"page":"344-348","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Ibrutinib-Induced Ventricular Electrical Storm Successfully Managed with Veno-Arterial ECMO and Intralipid Administration: A Rare Case Report"],"prefix":"10.4103","volume":"27","author":[{"given":"Debora E.","family":"Torre","sequence":"first","affiliation":[{"name":"Department of Cardiac Anesthesia and Intensive Care Unit, Cardiac Surgery, Ospedale Dell\u2019Angelo, Venice Mestre, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Stecco","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Institute of Human Anatomy, University of Padova, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Porzionato","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Institute of Human Anatomy, University of Padova, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Mangino","sequence":"additional","affiliation":[{"name":"Cardiac Surgery Department, Ospedale Dell\u2019Angelo, Venice Mestre, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Macchi","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Institute of Human Anatomy, University of Padova, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"De Caro","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Institute of Human Anatomy, University of Padova, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Pirri","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Institute of Human Anatomy, University of Padova, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"R1-20241226","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","article-title":"Management of adverse effects\/toxicity of ibrutinib","volume":"136","author":"Paydas","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"R2-20241226","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R3-20241226","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.2147\/DDDT.S377697","article-title":"Ibrutinib-associated cardiotoxicity: From the pharmaceutical to the clinical","volume":"16","author":"Dong","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"R4-20241226","doi-asserted-by":"crossref","first-page":"987008","DOI":"10.3389\/fcvm.2022.987008","article-title":"Mechanical circulatory support in ventricular arrhythmias","volume":"9","author":"Tavazzi","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R5-20241226","doi-asserted-by":"crossref","first-page":"73","DOI":"10.21037\/atm.2017.01.39","article-title":"Extracorporeal life support for refractory ventricular tachycardia","volume":"5","author":"Bhandary","year":"2017","journal-title":"Ann Transl Med"},{"key":"R6-20241226","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/0885066612445978","article-title":"Intravenous lipid emulsion for the treatment of drug toxicity","volume":"29","author":"Ozcan","year":"2014","journal-title":"Intensive Care Med"},{"key":"R7-20241226","doi-asserted-by":"crossref","first-page":"1840.e3","DOI":"10.1016\/j.ajem.2015.04.012","article-title":"Life-threatening flecainide overdose treated with intralipid and extracorporeal membrane oxygenation","volume":"33","author":"Brumfield","year":"2015","journal-title":"Am J Emerg Med"},{"key":"R8-20241226","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1080\/17425255.2016.1239717","article-title":"Pharmacokinetic and pharmacodynamics evaluation of ibrutinib fot the treatment of chronic lymphocytic leukemia: Rationale for lower doses","volume":"12","author":"Bose","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R9-20241226","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/CNQ.0000000000000082","article-title":"Continuous intravenous antiarrhythmic agents in the intensive care unit: Strategies for safe and effective use of amiodarone, lidocaine, and procainamide","volume":"38","author":"Samarin","year":"2015","journal-title":"Crit Care Nurs Q"},{"key":"R10-20241226","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s13181-016-0550-z","article-title":"ACMT position statement: Guidance for the use of intravenous lipid emulsion","volume":"13","year":"2017","journal-title":"J Med Toxicol"},{"key":"R11-20241226","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.ajem.2014.05.019","article-title":"Intralipid emulsion treatment as an antidote in lipophilic drug intoxications","volume":"32","author":"Eren","year":"2014","journal-title":"Am J Emerg Med"},{"key":"R12-20241226","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/15563650.2015.1004582","article-title":"What are the adverse effects associated with the combined use of intravenous lipid emulsion and extracorporeal membrane oxygenation in the poisoned patient?","volume":"53","author":"Lee","year":"2015","journal-title":"Clin Toxicol"},{"key":"R13-20241226","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"key":"R14-20241226","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1097\/MAT.0000000000001725","volume":"68","year":"2022","journal-title":"ASAIO J"}],"container-title":["Annals of Cardiac Anaesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aca.aca_4_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:06:29Z","timestamp":1787774789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aca.aca_4_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/aca.aca_4_24","relation":{},"ISSN":["0971-9784","0974-5181"],"issn-type":[{"value":"0971-9784","type":"print"},{"value":"0974-5181","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"assertion":[{"value":"2024-01-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}